JP2011504474A5 - - Google Patents

Download PDF

Info

Publication number
JP2011504474A5
JP2011504474A5 JP2010534409A JP2010534409A JP2011504474A5 JP 2011504474 A5 JP2011504474 A5 JP 2011504474A5 JP 2010534409 A JP2010534409 A JP 2010534409A JP 2010534409 A JP2010534409 A JP 2010534409A JP 2011504474 A5 JP2011504474 A5 JP 2011504474A5
Authority
JP
Japan
Prior art keywords
use according
disease
medicament
inhibitor
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010534409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504474A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/009880 external-priority patent/WO2009065596A2/en
Publication of JP2011504474A publication Critical patent/JP2011504474A/ja
Publication of JP2011504474A5 publication Critical patent/JP2011504474A5/ja
Pending legal-status Critical Current

Links

JP2010534409A 2007-11-22 2008-11-21 アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用 Pending JP2011504474A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07022695 2007-11-22
PCT/EP2008/009880 WO2009065596A2 (en) 2007-11-22 2008-11-21 Use of mnk inhibitors for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2011504474A JP2011504474A (ja) 2011-02-10
JP2011504474A5 true JP2011504474A5 (enExample) 2011-12-22

Family

ID=40404966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534409A Pending JP2011504474A (ja) 2007-11-22 2008-11-21 アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用

Country Status (5)

Country Link
US (1) US20100247517A1 (enExample)
EP (1) EP2219649A2 (enExample)
JP (1) JP2011504474A (enExample)
CA (1) CA2706203A1 (enExample)
WO (1) WO2009065596A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1899353A1 (en) * 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
EA200802118A1 (ru) 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
BRPI0812398A2 (pt) * 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
NZ591113A (en) 2008-08-26 2012-07-27 Boehringer Ingelheim Int Thienopyrimidine linked to phenyl or pyridine via an nh amine for pharmaceutical compositions
EA201201191A1 (ru) * 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
AR080328A1 (es) * 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
ES2649995T3 (es) * 2011-07-18 2018-01-16 Merck Patent Gmbh Benzamidas
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
GB201520499D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
TWI762579B (zh) 2017-02-14 2022-05-01 美商伊凡克特治療公司 六氫吡啶經取代之ＭｎＫ抑制劑及其相關方法
JP2022505846A (ja) 2018-10-24 2022-01-14 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ阻害剤の結晶形態

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
ATE486592T1 (de) * 2004-01-05 2010-11-15 Merz Pharma Gmbh & Co Kgaa Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
EP1899353A1 (en) * 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
MX2008012479A (es) * 2006-03-29 2009-08-13 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas.
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
EA200802118A1 (ru) * 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
WO2007127273A2 (en) * 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
DE602007004618D1 (de) * 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren

Similar Documents

Publication Publication Date Title
JP2011504474A5 (enExample)
JP5657556B2 (ja) α７選択的リガンドを用いる治療
IL191311A (en) Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2279727A3 (en) Nanoparticulate aripiprazole formulations
JP2010535801A5 (enExample)
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
WO2007136518A3 (en) Treatment of autoimmune disorders
JP2015520221A5 (enExample)
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
CY1105507T1 (el) Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες
RU2013154699A (ru) Сцилло-инозитол для применения в лечении поведенческих и психических расстройств
JP2015500223A5 (enExample)
JP2016510343A5 (enExample)
JP2012531402A5 (enExample)
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
JP2009178162A5 (enExample)
JP2020527172A5 (enExample)
JP2010526884A5 (enExample)
JP2012511571A5 (enExample)
JP2005281314A5 (enExample)